• 1

    Marsden PD, 1986. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans R Soc Trop Med Hyg 80 :859–876.

  • 2

    Lucas CM, Franke ED, Cachay MI, Tejada A, Cruz ME, Kreutzer RD, Barker DC, McCann SHE, Watts D, 1998. Geographic distribution and clinical description of leishmaniasis cases in Peru. Am J Trope Med Hyg 59 :312–317.

    • Search Google Scholar
    • Export Citation
  • 3

    Guthmann JP, Arlt D, Garcia LM, Rosales M, de Jesus Sanchez J, Alvarez E, Lonlas S, Conte M, Bertoletti G, Fournier C, Huari R, Torreele E, Llanos-Cuentas A, 2005. Control of mucocutaneous leishmaniasis, a neglected disease: Results of a control programme in Satipo Province, Peru. Trop Med Int Health 10 :856–862.

    • Search Google Scholar
    • Export Citation
  • 4

    Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G, 2005. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimonate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40 :1395–1403.

    • Search Google Scholar
    • Export Citation
  • 5

    Berman J, 2005. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 14 :1337–1346.

  • 6

    Berman JD, 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24 :684–703.

    • Search Google Scholar
    • Export Citation
  • 7

    Croft SL, 2001. Monitoring drug resistance in leishmaniasis. Trop Med Intern Health 6 :899–905.

  • 8

    Llanos-Cuentas A, Echevarria J, Cruz M, La Rosa A, Campos P, Campos M, Franke E, Berman J, Modabber F, Marr J, 1997. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of micosal leishmaniasis. Clin Infect Dis 25 :677–684.

    • Search Google Scholar
    • Export Citation
  • 9

    Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD, 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113 :934–940.

    • Search Google Scholar
    • Export Citation
  • 10

    Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD, 1994. Efficacy of 2-day and 4-day regimens of sodium stibogluconate (pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51 :77–82.

    • Search Google Scholar
    • Export Citation
  • 11

    Marsden PD, Llanos-Cuentas EA, Lago EL, Cuba CC, Barreto AC, Costa JM, Jones TC, 1984. Human mucocutaneous leishmaniasis in tres bracos, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev Soc Bras Med Trop 17 :179–186.

    • Search Google Scholar
    • Export Citation
  • 12

    Harbath S, Burke J, Lloyd J, Evans R, Pestotnik S, Samore M, 2002. Clinical and economical outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35 :120–127.

    • Search Google Scholar
    • Export Citation
  • 13

    Andersen EM, Cruz-Saldarriaga ME, Llanos-Cuentas A, Cjuno ML, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD, 2005. Comparison of meglumine antimonate and pentamydine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 72 :133–137.

    • Search Google Scholar
    • Export Citation
  • 14

    Velez I, Agudelo S, Hendricks E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 126 :232–236.

    • Search Google Scholar
    • Export Citation
  • 15

    Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF, 1992. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165 :528–534.

    • Search Google Scholar
    • Export Citation
  • 16

    Mattock NM, Peters W, 1975. The experimental chemotherapy of leishmaniasis II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Annals of Tropical Medicine and Parsitology 69 :359–371.

    • Search Google Scholar
    • Export Citation
  • 17

    Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Brycesson A, 1994. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica.Trans R Soc Trop Med Hyg 88 :334–339.

    • Search Google Scholar
    • Export Citation
  • 18

    El-On J, Halevy S, Grunwald MH, Weinrauch L, 1992. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 27 :227–231.

    • Search Google Scholar
    • Export Citation
  • 19

    Soto J, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M, 2002. Treatment of cutaneous leishmaniasis with a topical anti leishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66 :147–151.

    • Search Google Scholar
    • Export Citation
  • 20

    Soto J, Hernandez N, Mejia H, Grogl M, Berman J, 1995. Successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 20 :47–51.

    • Search Google Scholar
    • Export Citation
  • 21

    Jha TK, Olliaro P, Thakur CPN, Kanyok TP, Singhania BL, Singh IJ, Singh NPK, Akhourny S, Jha S, 1998. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316 :1200–1205.

    • Search Google Scholar
    • Export Citation
  • 22

    Thakur CP, Kanvok TP, Pandey AK, Sinha GP, Messick C, Olliaro P, 2000. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94 :432–433.

    • Search Google Scholar
    • Export Citation
  • 23

    Romero GAS, Lessa HA, Orge MGO, Macedo VO, Marsden PD, 1998. Mucosal leishmaniasis treatment with aminosidine sulphate: results of two-year follow-up. Rev Soc Bras Med Trop 31 :511–516.

    • Search Google Scholar
    • Export Citation
  • 24

    Lopez M, Inga R, Cangalaya M, Echevarría J, Llanos-Cuents A, Arevalo J, 1993. Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work. Am J Trop Med Hyg 49 :348–356.

    • Search Google Scholar
    • Export Citation
  • 25

    Soto J, Grogl M, Berman J, Olliaro P, 1994. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88 :695–698.

    • Search Google Scholar
    • Export Citation
  • 26

    Hepburn NC, Tidman MJ, Hunter JAA, 1994. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Top Med Hyg 88 :700–703.

    • Search Google Scholar
    • Export Citation
  • 27

    Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. 1995. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35 :577–584.

    • Search Google Scholar
    • Export Citation
  • 28

    Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19 :111–126.

  • 29

    Thakur CP, Kanvok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P, 2000. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94 :429–431.

    • Search Google Scholar
    • Export Citation
  • 30

    Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 5 :763–774.

    • Search Google Scholar
    • Export Citation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

PARENTERAL AMINOSIDINE IS NOT EFFECTIVE FOR PERUVIAN MUCOCUTANEOUS LEISHMANIASIS

View More View Less
  • 1 Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Departamento de Enfermedades Infecciosas, Tropicales y Dermatológicas. Hospital Nacional Cayetano Heredia. Lima, Peru; Departamento de Medicina, Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia; Departamento de Medicina del Hospital Nacional Sur Este, Essalud Cuzco, Perú; Hospital Regional del Cuzco, MINSA, Peru; Facultad de Salud Pública y Administración. Universidad Peruana Cayetano Heredia, Lima, Peru; London School of Hygiene and Tropical Medicine,United Kingdom
Restricted access

Few therapeutic options are available for mucocutaneous leishmaniasis (MCL). We conducted a randomized open trial to evaluate the efficacy, safety, and tolerance of parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days compared with intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days in patients with moderate MCL in Cuzco, Peru. Cure was defined as complete healing with re-epithelialization within 1 year of follow-up. The trial was stopped after 38 patients were enrolled (17 in the MA group and 21 in the AS group) because of marked differences in response. Study groups were comparable in baseline characteristics. Cure rates were 0/21 in the AS group compared with 8/17 (47%, 95% confidence interval: 23–71%) in the MA group (P < 0.001). Side effects and laboratory abnormalities were mild in both groups. We conclude that parenteral AS given on its own is not effective for MCL in Peru.

Save